KisoJi has created the world’s largest single-domain antibody database—over 30 million validated antibodies—to train and power its proprietary AI platform. 

• KisoMouse: The world's only multi-species camelid transgenic mouse.
• KisoSeek: AI tools for paratope mapping and structural antibody search. **NEW** generative AI approaches leading to functional agonist antibodies against multiple cardiometabolic GPCR targets
• KisoBody: A cutting-edge platform for generating multispecific antibodies with unprecedented yield.

KisoJi’s lead program, KJ-103, is a first-in-class naked TROP2 antibody entering the clinic in 2026. KJ-103 shows potent anti-tumor activity in multiple solid tumors, on par with the efficacy of ADCs, yet without a cytotoxic payload.

Additionally, KisoJi has developed a number of agonist antibodies to incretin GPCR targets, including apelin, GLP1, GICR, and GCGR. These are being assembled into a multi-mechanism multi-specific cardiometabolic antibody that is muscle sparing.